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STAGING, PROGNOSIS, AND TREATMENT OF MERKEL CELL CARCINOMA:
A POPULATION-BASED STUDY
Douglas M. Housman, Benjamin D. Smith, and Lynn D. Wilson. Department of Therapeutic Radiology, Yale
University, School of Medicine, New Haven, CT.

Merkel cell carcinoma (MCC) is a rare form of skin cancer, often described as the most aggressive
cutaneous malignancy. Its high propensity for dermal-lymphatic invasion, local recurrence, and rapid lymphatic
and distant metastasis poses a significant treatment challenge to clinicians. Combining its highly aggressive
nature with its low incidence, merkel cell carcinoma is a particularly difficult cancer to study. Two major
staging criteria exist for Merkel cell carcinoma.
The purpose of this study is to validate and compare the Memorial Sloan Kettering Cancer Center
(MSKCC) staging criteria with the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis
(TNM) staging criteria for Merkel cell carcinoma (MCC) utilizing the Surveillance, Epidemiology, and End
Results (SEER) database. The role of radiation therapy (RT) is also evaluated.
1556 cases of MCC from the SEER database (1988-2002) were identified and evaluated. Tumor size,
lymph node status, and metastases were staged according to the MSKCC and AJCC TNM staging criteria
respectively (n = 561). The primary outcome was overall survival. Covariates included: age at diagnosis, site
of primary, receipt of radiation therapy, and MSKCC or AJCC stage respectively. Kaplan-Meier survival
analyses and Cox proportional hazards regressions were analyzed using SAS 9.1.
The median age was 75 years (range: 22-98) with 39% of patients being female. The median follow
up was 2.2 years with a range of 0.4-14.3 in the staged populations. Under the MSKCC staging criteria: fiveyear overall survival was 59% for stage I (n=224), 45% for stage II (n=114), 33% for stage III (n=140), and
28% for stage IV (n=83). When compared with stage I, the adjusted mortality HR was 1.44 (95% CI 1.03-2.00)
for stage II, 2.14 (95% CI 1.57-2.93) for stage III, and 2.61 (95% CI 1.85-3.67) for stage IV. Under AJCC
TNM staging criteria: five-year overall survival was 60% for stage I (n=223), 47% for stage II (n=107), 31% for
stage III (n=148), and 28% for stage IV (n=83). When compared with stage I, the adjusted mortality HR was
1.41 (95% CI 0.99-1.99) for stage II, 2.13 (95% CI 1.57-2. 89) for stage III, and 2.62 (95% CI 1.86-3.69) for
stage IV. Among 478 patients with local or regional disease, 49% received radiation. After adjusting for
MSKCC stage and age, radiation was not associated with survival, mortality HR 0.83 (95% CI 0.63-1.09). The
interaction of radiation with stage was not significant (P=0.69). Similarly, in the AJCC TNM staged
population, radiation was not associated with survival, mortality HR 0.83 (95% CI 0.63-1.09), with no
interaction of radiation with stage (P=0.42).
The MSKCC staging criteria appropriately and significantly risk stratified MCC within this SEER
population. Alternately, the AJCC staging criteria did not significantly risk stratify MCC within this SEER
population. The MSKCC criteria appears to better risk stratify MCC than the AJCC staging criteria, within this
SEER population. Radiation does not appear to confer a survival advantage among SEER patients with local or
regional disease.
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STAGING, PROGNOSIS, AND TREATMENT OF MERKEL CELL CARCINOMA:
A POPULATION-BASED STUDY
Douglas M. Housman, Benjamin D. Smith, and Lynn D. Wilson. Department of Therapeutic Radiology,
Yale University, School of Medicine, New Haven, CT.

Merkel cell carcinoma (MCC) is a rare form of skin cancer, often described as the most aggressive
cutaneous malignancy. Its high propensity for dermal-lymphatic invasion, local recurrence, and rapid
lymphatic and distant metastasis poses a significant treatment challenge to clinicians. Combining its highly
aggressive nature with its low incidence, merkel cell carcinoma is a particularly difficult cancer to study.
Two major staging criteria exist for Merkel cell carcinoma.
The purpose of this study is to validate and compare the Memorial Sloan Kettering Cancer Center
(MSKCC) staging criteria with the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis
(TNM) staging criteria for Merkel cell carcinoma (MCC) utilizing the Surveillance, Epidemiology, and End
Results (SEER) database. The role of radiation therapy (RT) is also evaluated.
1556 cases of MCC from the SEER database (1988-2002) were identified and evaluated. Tumor
size, lymph node status, and metastases were staged according to the MSKCC and AJCC TNM staging
criteria respectively (n = 561). The primary outcome was overall survival. Covariates included: age at
diagnosis, site of primary, receipt of radiation therapy, and MSKCC or AJCC stage respectively. KaplanMeier survival analyses and Cox proportional hazards regressions were analyzed using SAS 9.1.
The median age was 75 years (range: 22-98) with 39% of patients being female. The median
follow up was 2.2 years with a range of 0.4-14.3 in the staged populations. Under the MSKCC staging
criteria: five-year overall survival was 59% for stage I (n=224), 45% for stage II (n=114), 33% for stage III
(n=140), and 28% for stage IV (n=83). When compared with stage I, the adjusted mortality HR was 1.44
(95% CI 1.03-2.00) for stage II, 2.14 (95% CI 1.57-2.93) for stage III, and 2.61 (95% CI 1.85-3.67) for
stage IV. Under AJCC TNM staging criteria: five-year overall survival was 60% for stage I (n=223), 47%
for stage II (n=107), 31% for stage III (n=148), and 28% for stage IV (n=83). When compared with stage I,
the adjusted mortality HR was 1.41 (95% CI 0.99-1.99) for stage II, 2.13 (95% CI 1.57-2. 89) for stage III,
and 2.62 (95% CI 1.86-3.69) for stage IV. Among 478 patients with local or regional disease, 49%
received radiation. After adjusting for MSKCC stage and age, radiation was not associated with survival,
mortality HR 0.83 (95% CI 0.63-1.09). The interaction of radiation with stage was not significant
(P=0.69). Similarly, in the AJCC TNM staged population, radiation was not associated with survival,
mortality HR 0.83 (95% CI 0.63-1.09), with no interaction of radiation with stage (P=0.42).
The MSKCC staging criteria appropriately and significantly risk stratified MCC within this SEER
population. Alternately, the AJCC staging criteria did not significantly risk stratify MCC within this SEER
population. The MSKCC criteria appears to better risk stratify MCC than the AJCC staging criteria, within
this SEER population. Radiation does not appear to confer a survival advantage among SEER patients with
local or regional disease.
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INTRODUCTION:
Merkel cell carcinoma (MCC) is a particularly rare form of skin cancer. Derived from neuroendocrine origin,
MCC has been described as the most aggressive form of cutaneous malignancy. MCC appears to have a
predilection for the elderly and a propensity for dermal-lymphatic invasion along with rapid nodal and
hematogenous spread. The tumor has been shown to share many similarities with small-cell carcinoma of the
lung, including treatment options and metastatic potential. Although treatment regimes often include combined
modality therapy, early detection and complete surgical resection remain the foundation of the best treatment
outcomes. Unfortunately, MCC is a relatively poorly understood cancer. Current management tends to be
based on institutional experience and convention, with limited literature to support specific treatments. The
majority of literature is represented by single institution, retrospective, observational case studies with
populations significantly low enough to preclude definitive conclusions. Two major factors contribute to this
relatively limited fund of knowledge that exists in the current literature. Both its rarity and aggressive nature
raise research challenges that few studies have been able to overcome. In addition to the limited number of
treatment studies, there remains no consensus with respect to staging. The two staging systems most commonly
used in the literature are the Memorial Sloan Kettering Cancer Center (MSKCC) staging system for MCC and
the American Joint Committee on Cancer (AJCC) staging system for non-melanoma skin cancer. There has not
been a study that compares these staging systems or validates their respective staging criteria to the knowledge
of these authors. All of these factors combine, creating a multitude of treatment challenges for the clinician. (1)
(2, 3)
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BACKGROUND:
Discovery of the Merkel Cell:
The Merkel Cell was first described in 1875 by Frederick Merkel. He found a unique epidermal cell in the
snout skin of the mole that he named, “Tastzell” (tactile), indicating his belief that this cell represented a special
sensory cell of the skin. Merkel later identified this particular round cell in the basal layers of normal human
epidermis. (see figure below) The human homologue to this cell is referred to as a “Merkel cell.” Merkel
observed that these cells were associated with hair follicles, as a component of the tactile hair disk of Pinkus.
These cells formed complexes with the terminal nerve endings, relaying information related to the perception of
mechanical stimuli. The cells are purported to be slow adapting cutaneous mechanoreceptors, providing
information about touch and hair movement. Merkel cells have also been found as isolated cells in the
epidermis, the dermis, nail bed, and oral cavity. The cells are of neuroendocrine origin, migrating from the
neural crest to the skin, whereupon they finally differentiate into mature Merkel Cells. As such, Merkel Cells
express several neuronal and epithelial cell surface molecular markers. (1, 4-6)

(1)

7
First Case Reports of MCC:
In 1972 Toker reported on the five cases of “trabecular-cell carcinoma” of the skin, later renamed Merkel Cell
Carcinoma. In this seminal article, Toker is the first to describe the pathohistological findings of hematoxyloneosin stained surgical sections. He noted that all growths originated within the dermis or intermediate subcutis,
and displayed a uniform morphology. (7) The cells were composed of solid trabeculae that lacked acini. (7)
Toker observed abundant mitotic and apoptotic figures in many of the specimens. All of the cases were in an
elderly population with an age range of 65-76 and median age of 70. The derivation of these cells was not clear
to Toker. Originally, he believed these tumors might be cutaneous carcinoid, though they lacked carcinoidal
granules. (7) He also postulated that perhaps they came from sweat glands or hair follicles, though no
carcinomatous changes had ever previously been noted in the literature. (7) From this small study tumor size
was observed to correlate with prognosis, with larger, faster growing tumors carrying the worst prognosis. (7)
Interestingly enough, these initial case reports described as an indolent tumor of low malignant potential. (7)
He also pointed out that this unique tumor carried some diagnostic confusion, as 3 of the 5 cases were
misinterpreted as cutaneous metastatases from visceral anaplastic tumors. (3, 7, 8)
In 1978, three more cases of trabecular carcinoma of the skin came to the attention of Tang and Toker, who
subjected them to ultrastructural studies.(9) It was electron microscopy that facilitated confirmation that
trabecular carcinoma of the skin was indeed a unique entity as it was ultrastructurally distinct from other
diagnoses.(9) Tang and Toker proposed that the cells involved in trabecular carcinoma of the skin were of
neuralcrest origin and most likely Merkel cells.(9) They described the dense core granules on electron
microscopy found in all three trabecular carcinoma of the skin tumors examined in their study confirming its
neuralcrest origin.(9) The ultrastructural studies conclusively excluded the possibility that trabecular carcinoma
of the skin originated from other sources such as epidermis, sweat gland, and hair follicle.(9) Tang and Toker
noted that trabecular cell carcinoma is most often located in the upper dermis and occasionally the epidermis.(9)
Furthermore, electron microscopy allowed Tang and Toker to nominate the Merkel cell as the most likely
candidate of neuralcrest derivation when the micrographs appeared consistent with prior descriptions of Merkel
cells.(9) This observation was supported by Hashimoto’s theory that after separating from the Schwann cells,
Merkel cells migrate through the mesenchyme in the dermis, toward epidermis, where they eventually settle. (3,
8-10)

MCC in the 1980’s:
By 1980 a total of 10 cases had been reported in the literature, and was now being referred to as neuroendocrine
carcinoma of the skin, eventually throughout the 80’s and 90’s merkel cell carcinoma was eventually adopted.
At that point, enough histological and ultrastructural studies of MCC had begun to elucidate the prior diagnostic

8
confusion, enabling epidemiological, prognostic, and treatment focused research while still maintaining the
descriptive nature of most published studies. Before the diagnosis of MCC could be made, the following
alternative diagnoses had to be systematically excluded: small-cell squamous carcinoma, malignant melanoma,
histiocytosis X, eccrine sweat gland carcinoma, metastatic small-cell carcinoma of the lung, metastatic islet cell
carcinoma, metastatic small-cell lymphoma, and either metastatic or primary cutaneous neuroblastoma. (6) In
later years, immunohistochemical staining for neuron-specific enolase and other markers improved the ability to
diagnose MCC. (11-13) By 1983, about 86 patients with trabecular carcinoma or Merkel cell tumor had been
described in the literature. The overwhelming treatment recommendation was primary surgical resection.
Recurrences were treated with radiation therapy and/or chemotherapy with varying degrees of success. (1, 4, 6,
8-10, 14-16)
Despite improving ability to diagnose this rare malignancy, information about the natural history, epidemiology,
and clinical features of MCC remained scarce because studies were hindered by the challenges related to its rare
occurrence, multiple names (trabecular carcinoma of the skin, neuroendocrine carcinoma, and finally merkel
cell carcinoma), MCC’s unclear origin, and the long differential diagnosis which contained other primary and
metastatic skin lesions. What was known about MCC was mainly derived from case series and literature
reviews that compiled previously published case studies. This led to gaps and inconsistencies with respect to
epidemiologic and survival data. (17)

Epidemiology:
A more efficient approach to the epidemiology of MCC has been achieved by utilizing the Survival,
Epidemiology and End Result (SEER) Program. The Surveillance, Epidemiology, and End Results (SEER)
Program of the National Cancer Institute (NCI) is an authoritative source of information on cancer incidence
and survival in the United States. SEER has been collecting cancer specific data over the last thirty-plus years.
Subjects with cancer registered by SEER are uniquely identified, allowing more than one cancer to be recorded
for the same individual for as long as he or she lives in a SEER area. All subjects are followed annually to
determine their vital status. SEER publishes cancer incidence and survival data from population-based cancer
registries covering approximately 26 percent of the US population. The program began collecting data on
January 1, 1973 in the following states and metropolitan cities: Connecticut, Iowa, New Mexico, Utah, Hawaii,
Detroit, and San Francisco-Oakland. Between 1974-75, Atlanta and the Seattle-Puget Sound were added to
form the SEER-9. Ten predominantly black rural counties in Georgia were added in 1978, followed by the
Native Americans living in Arizona, in 1980. Other regions participated in the SEER program prior to 1990:
New Orleans, LA (1974-1977, rejoined 2001); New Jersey (1979-1989, rejoined 2001); and Puerto Rico (19731989). SEER also has been collecting information from an independent NCI tumor registry in Alaska. In 1992,
SEER expanded coverage of minority populations by adding, Los Angeles County and 4 counties in San Jose-
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Monterey area. In 2001, SEER expanded again to include: Kentucky, the rest of California, and reinstated New
Jersey and Louisiana. Currently SEER coverage includes 23 percent of African Americans, 40 percent of
Hispanics, 42 percent of American Indians and Alaska Natives, 53 percent of Asians, and 70 percent of
Hawaiian/Pacific Islanders. (18)
A SEER analysis in 1999 was the first large population epidemiological studies of MCC. Miller and Rabkin
looked at 424 cases of MCC as compared with melanoma between the years of 1986-1994 from the SEER 9
registries. They found the actual age adjusted incidence of MCC to be 0.23 in 100,000 people in white
populations, with only one-twentieth of the incidence in black populations. (17) Among whites, the ratio of
MCC to melanoma was about 1 to 65. (17) The following graph represents the regional incidences of MCC
and melanoma as correlated with UVB index:

(17)
Regional incidence rates for both cancers increased with increasing sun exposure as measured by UVB index.
One of the most sun exposed areas of the body, the face, was the location of 36% of MCC compared with only
14% of melanoma. Both cancers were noted to have increased frequency and aggressiveness in the
immunocompromized patient. (17)
In 2003 the second SEER analysis by Agelli and Clegg identified that the incidence of MCC was markedly
higher in males (0.34) over females (0.17). Agelli and Clegg looked at 1034 cases from the time period of
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1973-1999. They broke their analysis up into two groups the 1973-1991 using the SEER-9 database and 19921999 using the SEER-11, which included metropolitan Los Angeles and San Jose-Monterey, California. (19)
Agelli and Clegg reported the following demographic characteristics of their population: (19)
•

Median age: 74 (age range: 8-101)

•

Mean age: 72.3

•

Males: 56.3%

•

Females: 43.7%

•

Stage at diagnosis (According to SEER Historic Stage A * )(18):

•

o

Localized: 49.0%

o

Regional: 27.2%

o

Distant: 7.8%

o

Unstaged: 16.0%

Race:
o

White: 93.6%

o

Black: 1.2%

o

Other: 3.6%

o

Unknown: 1.6%

Agelli and Clegg reported that MCC occurred mostly in whites (~94%), in people over the age of 65 (~76%),
and in the head or neck region (~48%). They reported the five year survival based on SEER historic staging
criteria, localized (~75%), regional (~59%) and distant (~25%). Additionally, they identified the following as
positive predictors of survival: female sex, limb presentation, localized disease, and younger age. (19)

*

SEER Historic Stage A description taken from the SEER Data dictionary available at
www.seer.cancer.gov:
Localized — An invasive neoplasm confined entirely to the organ of origin. It may include
intraluminal extension where specified. For example for colon, intraluminal extension limited to
immediately contiguous segments of the large bowel is localized, if no lymph nodes are involved.
Localized may exclude invasion of the serosa because of the poor survival of the patient once the
serosa is invaded.
Regional — A neoplasm that has extended 1) beyond the limits of the organ of origin directly into
surrounding organs or tissues; 2) into regional lymph nodes by way of the lymphatic system; or 3) by
a combination of extension and regional lymph nodes.
Distant — A neoplasm that has spread to parts of the body remote from the primary tumor either by
direct extension or by discontinuous metastasis (e.g., implantation or seeding) to distant organs,
issues, or via the lymphatic system to distant lymph nodes.
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In 2005, another SEER analysis by Hodgson, 1124 cases of MCC were identified between the years of 19862001 from the SEER-9 registries. (20) Hodgson reported on the age adjusted incidence trends of MCC in
relation to other cancers and within certain subgroups of the MCC population. (20) The overall age-adjusted
incidence increased from 0.15 cases per 100,000 in 1986 to 0.44 cases per 100,000 in 2001. (20) See Figure
below:

(20)
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The estimated annual percent chance over that time period was 8.08%, indicating an incidence increase of ~8%
per year, compared with melanoma which had an estimated annual percent change of 3.03% per year. (20)
Hodgson reported the age-specific incidence rate trends, demonstrating an increase of incidence rates with age
between 5-year age groups and within 5-year age groups from 1986 to 2001. (20) See table below:

(20)
Hodgson also noticed an almost three-fold higher incidence in males over females. Although Hodgson accepts
that the ability to diagnose disease has significantly increased for cancers like melanoma and MCC, the
discrepancy between the two is most likely significant for actual and worry some increases in incidence. (20)
Although with a cancer like MCC that has a particular predilection for the elderly, the growing elderly
population that continues to live longer than previous generations may contribute to some of this proposed
increased incidence, in addition to the increased ability to diagnose with time. (20)
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Clinical Features:
At the time of diagnosis, MCC typically presents as a flesh-colored, red or violaceous intracutaneous mass with
a shiny surface. The lesion is usually painless, firm, and non-tender. MCC tends to grow quite rapidly and
often with overlying telangiectasias. Most commonly, the tumor is nodular but may also have plaque-like
features. These tumors can resemble basal-cell carcinoma, amelanotic melanomas, squamous-cell carcinoma,
and cutaneous lymphomas. (1, 3, 21, 22) (See images below)

(23)

(21)
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(24)

(25)

15

(26)

(27)

16

(23)
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(1)
MCC tumor size ranges from 2 – 200 mm. Most common presentations have been reported as less than 20mm,
though some studies maintain the median lesion size to be 20mm. (1, 3, 21, 22)
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Although the most common presentation of MCC is a head and neck primary in a sun-exposed region, skin
lesions can occur on the trunk, oral mucosa, genitalia, and perianal region in a random distribution. (28, 29) In
the face, the eyelids are commonly involved. In 2000, a review of 661 published cases, Tai et al. described the
following distribution: (22)
•

Head and Neck: 47%

•

Extremities: 33%

•

Trunk: 10%

•

Vulva: 2%

•

Multiple sites: <1%

In 2001, similar distribution was described by Medina-Franco et al. in a case series and literature review of
1024 cases. (30)
•

Head and Neck: 40.6%

•

Extremities: 33%

•

Trunk: 23%

•

Unknown: 3%

In 2003, an analysis of the SEER-11 data (1973-1999), Agelli and Clegg noted the following distribution in
1034 cases: (19)
•

Head and Neck: 48.3%

•

Upper Extremities: 19.3%

•

Lower Extremities: 16.2%

•

Trunk: 11.3%

•

Other: 5.2%

MCC can spread through the intricate dermal lymphatic system, resulting in the development of satellite
lesions. Regional nodes are involved clinically at presentation in about a third of cases. Hematogenous spread
occurs in about 50% of cases at some point in the course of the illness. Nodal status is the strongest predictor of
distant involvement. (1, 3, 19, 21, 31-34) Secondary sites of involvement include: the aforementioned satellite
lesions of the skin (28%), lymph nodes (27%), liver (13%), lung (10%), bone (10%), and brain (6%). (35)
Some of the less common sites of metastasis include: oral mucosa, testis, and parotid gland. (35-38) Symptoms
are typically limited to local effects related to rapid tumor growth and/or lymph node involvement. (1, 3, 35-37)
Superior vena cava syndrome and some paraneoplastic neurological complications have been described. (1, 3,
21, 22, 31, 32, 34, 39-53)
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Pathology and Histology:
MCC has been believed to arise from Merkel cells that are located in the upper dermis and frequently extend
into the subcutaneous fat with the occasional involvement of basal layer of epidermis. (5, 54) Although an
overwhelming majority of the literature maintains that MCC derives from the Merkel cell, there remains some
controversy. (1, 3, 21, 55, 56) The fundamental assertion that MCC is of neuroendocrine origin, as established
by Tang and Toker and supported many others, is not necessarily the issue. (4, 6, 9, 12, 16, 56-58) That the
Merkel cell is the purported origin of MCC is the nidus of objection and suspicion. (56) Alternate hypotheses
have proposed that MCC perhaps originate from immature totipotential stem cells that acquire neuroendocrine
features during malignant transformation, based on the high focal concentrations of intermediate filaments and
the individual concentrations of specific intermediate filaments subtypes found in MCC. (56)
The tumor consists of small blue cells, with richly heterochromatic nuclei and minimal cytoplasm. (7-9, 21)
The cells are usually ovoid and up to 15 μm in diameter. (1, 54) The Nuclei have fine granular chromatin, with
few nucleoli. (1, 54) The tumor cells have high mitotic activity, with apoptotic figures abundant. (7-9, 21)
There are three characteristics that most exemplify MCC: vesicular nuclei with small nucleoli, high mitotic
activity, and apoptosis. (1, 54) Invariably the tumor demonstrates lymphovascular invasion. (6-9, 12, 16, 21,
59)
The following two images are examples of MCC cells stained by Allen et al. (54) These images appeared in
their 2001 Journal of Clinical Oncology article on immunohistochemical analysis of sentinel lymph nodes. (54)
The first image is a hematoxylin and eosin conventionally stained section of a MCC tumor found in the dermis.
(54) Notice the hyperchromatic tumor cells. (54) The second image is of metastatic MCC found in the
subcapsular sinus of a lymph node, also stained with hematoxylin and eosin. (54)
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There are three main histologic patterns of MCC: trabecular type, small cell type, and intermediate type, which
is most common. (1, 3, 21) No prognostic association has been linked to these different histologic subgroups,
as such they have no clinical relevance as of yet. (1, 3, 21) See images below.

(21)
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Etiology:
The exact etiology of MCC is unknown. Sun exposure is believed to play a significant role though the exact
mechanism remains unclear. MCC has been shown to have a higher incidence in sun exposed areas of the
body. (17, 19, 33) Regional incidence rates have correlated with increasing sun exposure as measured by UVB
index. (17, 19, 20) Agelli et al found a correlation between UVB index and incidence of MCC as did Miller et
al. (19) See figure below:

(19)
Co-presentation with other skin cancers for which sun exposure is a major risk factor is common. (17) MCC is
associated with a high incidence of other skin tumors and hematologic malignancies. In one report by Brenner
et al. 17 of 67 patients (25 %) with MCC had a second neoplasm, 50% of which were squamous cell cancers.
(60) The relationship between MCC and ultraviolet (UV) radiation has been further supported by the increased
incidence of MCC in populations of patients status post PUVA treatment. (3, 61)
However, etiological factors, other that sun exposure, are also likely to be involved. Many of the most deadly
cases of MCC, present in areas not typically exposed to the sun. (17, 19, 20) Another possible cause of MCC
may be an impaired immune system. Although no predisposing conditions have been directly and consistently
identified, the incidence has been shown to be increased in immunocompromised and iatrogenically
immunosuppressed patients. (3, 17, 41, 62-68) There have been several cases reported of MCC after chronic
lymphocytic lymphoma (3, 67-74), in the HIV population (3, 62, 63), and in transplant patients with iatrogenic
immunosuppresion (1, 3, 64-66, 75-77). Additionally, support for an immunological basis of etiology is seen in
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the increased incidence of secondary malignancies in MCC patients (25%), compared with melanoma (5.8%).
(17, 60) The standardized incidence ratio for a second cancer was 2.8 (95% confidence interval, 1.38 - 4.22).
(60) Compared to patients with MCC only, those who developed second neoplasms had significantly higher
MCC-specific mortality rate (65 versus 40 percent). (60) Additionally there have been several reports of
spontaneous remission, hypothesized to be immune mediated. (3, 78, 79) These reports suggest that the
immune system may play a significant role in the pathogenesis of MCC.

Pathogenesis:
There are several chromosomal abnormalities that have been described in MCC. These abnormalities may one
day help elucidate the unclear pathogenesis of MCC. However, to date there have been no conclusive evidence
to implicate specific tumor-supressor genes or oncogenes. (21, 80-82) The cytogenetic abnormality that has
raised much interest is the deletion of the short arm of chromosome 1 (1p36). (82-88) This deletion has been
seen in melanoma and neuroblastoma and gives more weight to the neuralcrest origin argument. (82-88)
Additionally, P73, a protein of similar structure and function to P53, has been localized to 1p36.33 and shown
to have been deleted in multiple neoplasms, including those of neuroendocrine origin. (82) C to T mutations
have been seen in the P73 protein leading to mis-sense and non-sense mutations, causing decreased expression
and activity of P73. (82) UVB radiation has been known to cause C to T point mutations. (82) Similar
mutations in P53 have been associated with more aggressive disease. Thus there exists some cytogenetic
evidence to support the purported link between sunlight and MCC, in the form of UVB induced mutations to
P53 and P73. (82-88)
Similarities between small-cell lung cancer and MCC have been demonstrated cytogenetically. (82-88) A
common feature of small-cell lung cancer, loss of heterozygosity of the short arm of chromosome 3 (3p21), has
been seen in MCC. (82-88) This region, (3p21), has been shown in lung and breast cancer to be associated with
a particular tumor suppressor gene in small-cell lung cancer, a Ras association domain family 1 gene
(RASSF1A). (21, 89)
A DNA-binding protein, POU4F3 – Merkel nuclear factor, has been identified in MCC. (80) The function of
this transcription factor has been examined in mice. Both POU4F3 and ATOH1 have been shown to be
essential to normal Merkel-cell function and for neuroendocrine differentiation. (80) The importance of these
transcription factors remains unclear. (80) Several other chromosomal abnormalities have been noted, namely,
trisomy of 1, 6, 11, or 18; and deletion of chromosome 7. (82-88) Loss of heterozygosity has been noted on
chromosomes 13 and the long arm of 10. (82-88) Despite all of these significant findings, the relationship
between these chromosomal abnormalities and a genetic basis of pathogenesis remains unclear. (82-88)
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Diagnosis:
A clinical suspicion of MCC must be substantiated by biopsy. (1, 3, 21, 31, 45, 90-94) As MCC can resemble
many different cutaneous neoplasms, careful effort must be made to unsure thoughtful evaluation. As described
earlier by Toker (7, 8) and Tang and Toker (9), it is difficult to accurately diagnose MCC by light microscopy
alone due to its similarity to other poorly differentiated small blue cell tumors, including small cell lung cancer,
neuroblastoma, amelanotic melanoma, sweat gland carcinoma, Ewing’s sarcoma, cutaneous large cell
lymphoma, Langerhans cell histiocytosis and various metastatic tumors i.e. metastatic carcinoid. (1, 3, 21, 31,
45, 90-95) Ultrastructural studies with electron microscopy and immunohistochemical staining are required to
make a definitive diagnosis. (6, 12, 59, 94) On electron microscopy the following characteristics are typical of
Merkel cells and MCC: paranuclear electron dense neurosecretory granules, 10nm filaments, and desmosomes.
(12)

(23)
Merkel cells exhibit immunohistochemical properties of both neuroendocrine and epithelial cells. (12, 21, 54,
55, 58, 96) As such, MCC tends to express both neuroendocrine (neuron-specific enolase, synaptophysin,
chromogranin) as well as cytokeratin markers (cytokeratin 20, CAM 5.2). (1, 3, 21, 54) Immunoreactivity for
various intermediate filaments, such as the subgroup of cytokeratins, help distinguish MCC from some of the
other undifferentiated tumor previously mentioned. (11-13, 42, 54-56, 91, 92, 96-98) The following chart from
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the 2002 review article in the Journal of Clinical Oncology by Goessling et al. summarizes the
immunohistochemical staining profile of MCC and the tumors within the working differential diagnosis. (21)

(21)
There are several cellular markers that have been identified that give MCC a unique fingerprint, improving
diagnostic sensitivity and specificity. The first of these markers was identified in 1983. (19) Neuron-specific
enolase (NSE) is a protein specific to neuroendocrine cells and as such, helps identify these cell types as
belonging to the neuroendocrine family. (91) However, this marker is not specific to MCC and often
contributes little help in narrowing the differential diagnosis. (54, 98) The second such marker is a
neurofilament protein (NFP) which appears as a paranuclear dot. (1, 21, 54) Next found was CAM 5.2, an
antibody that recognizes low molecular weight cytokeratins. The most significant of the markers was identified
in 1992, cytokeratin 20 (CK20) which is an intermediate filament found in cutaneous epithelial cells. (19, 21,
54, 98) See the following immunohistochemical stainings of MCC found in a series of sentinel node biopsies
by Allen et al. in 2001. They were stained with the following antibodies: Chromogranin, a neuroendocrine
differentiation marker; Cam5.2 which recognizes low molecular weight cytokeratins; and Cytokeratin 20, a
marker specific to cutaneous neuroendocrine tumors, not pulmonary variants. (54)
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(54)
The MCC profile most closely resembles that of small-cell lung cancer. As these tumors share many clinical
similarities, it is not surprising that their immunohistochemical profile is also similar. Notable
immunohistochemical differences between small-cell lung cancer and MCC are the preferential staining of CK7
and CK20 respectively. (21, 98) CK7 is a cytokeratin that identifies bronchial small-cell carcinoma.
Additionally, Small-cell melanoma has a similar immunohisochemical profile to MCC, sharing the NSE cell
marker. However, melanoma is CK20 negative, S100 positive, and NFP negative. (21)
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These markers have lead to direct improvements of detecting MCC. Perhaps contributing to the purported
increased incidence of MCC seen over the years, shown by Hodgson’s 2005 report on changing incidence
trends of MCC. (20) Agelli et al. illustrated this implied relationship in their 2003 article with the following
graph:

(19)
Official confirmatory immunihistochemical staining recommendations from the National Comprehensive
Cancer Network include: NSE, chromogranin A, pancytokeratin, NFP, CK20, and thyroid transcription factor-1.
(94) Additionally electron microscopy may also be helpful. (94)
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Staging:
Following histologically confirmed diagnosis, proper staging should be done to help patient and clinician
choose the best treatment. Proper staging is important for many reasons. Not only does staging allow
assessment of prognosis, but staging also helps direct therapy and establish standards of care. There is no
consensus with regard to staging system for MCC. There are two major staging systems that have been used in
the literature: the Memorial Sloan Kettering Cancer Center (MSKCC) MCC staging criteria and the American
Joint Committee on Cancer TNM staging criteria for non-melanoma skin cancer. The MSKCC staging criteria
was first reported in the literature in 1991 by Yiengpruksawan et al. with a series of 70 cases. (34) This staging
system remains the most common and is used by the National Cancer Institute. Originally the staging criteria
described three stages: local, regional, and metastatic, with a sub-stratification of the local disease population.
(34)

(34)
In the original article, Yiengpruksawan et al. did not note a significant difference in outcome of Stage Ia and
Stage Ib. (34) In subsequent reviews with larger numbers of cases reported, a significant difference between the
outcomes of different substages. (90) However, these three stages were later revised into a four stage system.
This revised staging system was published in the largest single institution (n = 251) case series (studied over a
32 year period), by Allen et al in 2005. (31)
In contrast with the MSKCC staging system, the AJCC TNM non-melanoma skin cancer staging system has
one subtle difference. (Highlighted yellow below) The T-stage T4, of the AJCC TNM staging criteria, upstages
tumors, regardless of size, from MSKCC stage I and MSKCC stage II, to stage III status. T4 includes direct
local invasion of extradermal structures deep to the tumor (e.g., cartilage, skeletal muscle, or bone). Although a
majority of the literature is based on the original or revised MSKCC staging criteria, some studies have used the
non-melanoma skin cancer TNM staging criteria from the AJCC to stage and classify MCC. (1-3, 21, 31, 34,
49, 50, 54, 90)
Neither staging system, the revised MSKCC nor the AJCC TNM, has been independently validated for the use
in staging MCC. Such a validation would be helpful in establishing consensus in staging such an aggressive
cancer. On the following two pages, both staging systems are outlined in detail.
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The MSKCC staging criteria
•

Primary tumor (T)
–
–

•

Regional lymph nodes (N)
–
–

•

T2, N0, M0

Stage III
–

•

T1, N0, M0

Stage II
–

•

M0: No distant metastasis
M1: Distant metastasis

Stage I
–

•

N0: Negative regional lymph nodes
N1: Positive regional lymph nodes

Distant metastasis (M)
–
–

•

T1: Tumor ≤ 2 cm in greatest dimension
T2: Tumor >2 cm in greatest dimension

Any T, N1, M0

Stage IV
–

Any T, any N, M1
(31)
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The AJCC TNM staging criteria
•

Primary tumor (T)
–
–
–
–

•

Regional lymph nodes (N)
–
–

•

T2, N0, M0
T3, N0, M0

Stage III
–
–

•

T1, N0, M0

Stage II
–
–

•

M0: No distant metastasis
M1: Distant metastasis

Stage I
–

•

N0: Negative regional lymph nodes
N1: Positive regional lymph nodes

Distant metastasis (M)
–
–

•

T1: Tumor ≤ 2 cm in greatest dimension
T2: Tumor >2 cm but ≤ 5 cm in greatest
dimension
T3: Tumor >5 cm in greatest dimension
T4: Tumor invades deepextradermal
structures

T4, N0, M0
Any T, N1, M0

Stage IV
–

Any T, any N, M1
(99)
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Staging Work-up:
After establishing a histologic diagnosis, patients should undergo further imaging for complete staging and
exclude other sites as primary sources of small-cell cancer. However, before such an involved diagnostic
imaging work-up, a thorough dermatological examination of the entire skin surface and draining nodes must be
complete with careful attention to assess possible satellite lesions, dermal seeding, and clinical
lymphadenopathy. (1, 3, 21, 31, 34, 54, 90, 94, 100) The proper staging investigations should include standard
blood tests, chest x-ray, computerized tomography (CT) of the chest and abdomen, and a head CT if the patient
is symptomatic. (1, 3, 21, 34, 94)

Computerized Tomography:
The CT of the chest should be performed to rule out the presence of a lung mass suspicious for either MCC
metastasis or small-cell lung cancer primary. The CT of abdomen and pelvis should be assessed for evidence of
metastasis. (1, 3, 21, 24, 101)
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(24)
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Magnetic Resonance Imaging:
The role of magnetic resonance imaging (MRI) is clear in the evaluation of neurologically symptomatic patients
and should be combined with consideration of lumbar puncture. (24)

(24)
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MRI for the staging outside of the central nervous system (CNS) is only beginning to be assessed and remains
unclear. One study thus far has sought to determine the MRI characteristic of MCC correlated with histology.
(102) Anderson et al. describes subcutaneous lymphatic reticular stranding, multiple subcutaneous masses, and
lymph node metastases with retained fatty tissue—all consistent with the soft tissue lymphatic nature of MCC
found on histologic sections. (102)

(102)

Nuclear Medicine:
Nuclear medicine has been revolutionary in staging many cancers, with positron emission tomography (PET)
using fluorodeoxyglucose and combined PET/CT scans. (1, 3, 21, 24, 101) Nuclear medicine continues to be at
the forefront of diagnostic imaging for MCC and other neoplasms, with active research extending into using
such specific tools to direct therapy. (1, 3, 21, 23, 24, 101, 103) In particular, somatostatin-receptor
scintigraphy PET, Octreoscan, has been teamed with specific targeted chemotherapy, Octreotide, with
impressive results in case reports. (1, 24, 44, 101, 102, 104) (103) (See Octreoscan below)
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(24)

Treatment:
Due to the rarity of MCC, no prospective clinical studies with statistical significance exist that have assessed
initial surgical therapy, radiation therapy, or chemotherapy. Randomized trials are virtually impossible due to
MCC’s rarity, with individual centers encountering only a few cases a year. MCC’s aggressive nature and
predilection for the elderly contribute to the challenges of studying this cancer and particularly to treating it. As
such the literature for the management of MCC is significantly limited. There is no definitive consensus on the
optimum management for early stage MCC, particularly regarding postoperative adjuvant treatment. Although
chemotherapy is often a component of treatment, its use is an extension of its efficacy in other neuroendocrine
tumors like small-cell lung cancer. Although the use of chemotherapy in recurrent or metastatic disease may be
effective its use is often challenging in the aged population. Most management decisions are based on empirical
institutional experience and convention. (1, 3, 21, 31, 54, 90)
What little consensus exists, points in the direction of supporting the primary treatment of aggressive surgical
resection. (1, 3, 21, 31, 34, 44, 54, 90) Surgical excision with tumor-free, wide margins is the primary therapy
for all localized disease. (1, 3, 21, 34, 53, 90, 105, 106) Most treatment guidelines recommend the margins to
be between 2 to 3 cm wide and about 2 cm deep for all local excisions of the tumor. (1, 3, 21, 34, 53, 90, 105,
106) These recommendations have limited supporting data. In a series of 38 patients at MSKCC, margins of >
3cm (n=11) were without local recurrence whereas those with 2 to 3cm margins (n=27) had 4 (15%) recurrence.
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(34) They noted a local recurrence of 26% as reported in their initial study. (34) On update, that recurrence
rate increased to 55%. (90) Several later studies found little to no benefit to survival whether margins were > or
< 2cm as well as no difference even if margins are less than 1cm. (1, 3, 21, 53, 105-107) The following are the
current surgical guidelines for MCC from the National Comprehensive Cancer Network: (94)

Mohs micrographic surgery has been purported to be more successful at controlling local disease than
traditional wide excision. (108, 109) One obvious advantage to Mohs surgery is the guaranteed negative margin
status by histologic examination of every excised specimen. Given that MCC often demonstrated local
extension into the muscle, deep margins may represent a potential site of failure, contributing to the high rate of
local and regional recurrence. Boyer et al reviewed 45 cases of MCC treated with Mohs micrographic surgery
with (n=20) or without (n=25) adjuvant radiation therapy (RT). (108) There were 4 recurrences in the non-RT
arm and none in the RT arm. (108) The numbers were too small to show a significant difference between
treatment arms. (108) Aside from the small population size, a significant limitation of this study was the
relatively short follow-up. The median follow-up time was 25 months for the non-RT arm and 14 for the RT
arm. (108) The role of Mohs micrographic surgery is still not proven though has some promise in treating
cosmetically sensitive areas. (1, 3, 21, 94, 108, 109)
Pathological involvement of regional lymph nodes is present in approximately 10-30% of patients who undergo
elective lymph node dissection and regional relapse in the nodal region occurs in up to 76% of cases. (1, 3, 21,
31, 32, 51, 52, 54, 90, 100, 104, 110) In some studies the incidence of micro-metastasis in elective lymph node
dissection has been reported as high as 100%. (110) As such, the role of sentinel node assessment via
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lymphoscintigraphy and/or biopsy is of particular interest for this aggressive malignancy. By far the most
convincing data yet to support sentinel node biopsy and other pathological nodal assessment comes from the
Allen et al. paper recently published in the Journal of Clinical Oncology. (31) Allen et al. looked at 251
patients treated at MSKCC from 1970-2002 with an average follow-up time of 40 months. In the population of
clinically node negative cases (n=71), pathological staging of the draining nodal basin detected 16 (23%) cases
of node positive disease. (31) Pathological nodal staging vs. clinical node staging significantly improved stagespecific survival outcomes. (31) Allen et al. and others have found similar findings in prior articles on sentinel
node biopsy with immunohistochemical analysis. (31, 32, 51, 54, 104) Sentinel node biopsy will likely have a
more prominent role in the future of MCC staging, conferring a considerable improvement in staging accuracy
without the significant morbidity of a full lymph node dissection. (32)
Because of the aggressive nature of MCC with high local and regional recurrence following surgery, many
authors have recommended postoperative radiation therapy on the basis of retrospective observational studies.
(30) However, the role of radiation therapy (RT) remains a highly contested issue. (1, 3, 21-23, 30, 31, 34, 41,
44, 49-53, 90, 106, 108, 111-118) Without looking at the literature everything would seem to point to the
definitive use of RT in the treatment of an aggressive cancer with high local and regional recurrence given that
it has notable similarities to small-cell lung cancer, which has particular radiosensitivity. Alas the evidence
remains controversial. (1, 3, 21-23, 30, 31, 34, 41, 44, 49-53, 90, 106, 108, 111-117) Given the retrospective
case review evidence base, current recommendations are for adjuvant RT at doses between 45 to 50 Gy
administered to the primary site and involved lymph nodes following surgical resection. (1, 3, 21, 44, 52, 94,
107, 111-113, 115-122) Radiation doses have been significantly correlated with overall survival, with doses
between 45 and 50 Gy being associated with the best outcome. (1, 21, 22, 94, 115, 118, 119, 121) The results
were poorer at doses greater than 50 Gy (possibly related to more aggressive tumors receiving more aggressive
radiation) and the outcomes were worse with RT doses < 45 Gy, suggesting 45 Gy as the minimum effective
dose. (1, 21, 22, 94, 115, 118, 119, 121) In a retrospective review of 661 mainly literature based cases, 169
received RT as a component of their initial treatment. (22) Adjuvant RT did not have a significant impact on
overall survival (p = 0.44), but was associated with significantly higher two-year disease-free interval (37
versus 24 percent) and a lower incidence of local recurrence at 18 months (21 versus 34 percent). (22) The best
support for the use of RT as adjuvant therapy in the treatment of MCC comes from the multimodality treatment
meta-analysis of MCC with 1024 cases from the literature. (30) Medina-Franco et al. included eleven case
series (n = 441) in the evaluation of the post operative RT for local recurrence. (30) The local recurrence rate
with radiation was 10.5% (range, 0–33%) vs. 52.6% (range, 6–100%) without radiation (P = .00001). (30)
They concluded that surgery and adjuvant radiotherapy were associated with a reduced risk of local recurrence
and appeared to provide the best local control. (30) (See table below)
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(30)
In the Allen et al. 2005 Journal of Clinical Oncology article, adjuvant RT was administered to 41 (17%) of 237
patients who presented with local or regional disease, representing the largest single institution experience with
MCC. (31) Although this review did not show an association with local recurrence (RT 10% v No RT 8%; P =
0.76) or nodal recurrence (RT 13% v No RT 26%; P = 0.13), the study may have been underpowered to reveal
any significant difference, given the relatively small number of patients who received RT. (31, 117) When
Wilson et al. raised this issue in a letter of correspondence, Allen et al. responded, “A randomized study
designed to demonstrate a reduction in local or regional recurrence from 12% to 6% with the addition of RT
would require 281 patients per arm (one-sided P _ .05, power 0.8), a study that will clearly never be
undertaken.” (117) Alas since none of the evidence is based on prospective randomized studies, there are
significant selection biases which may be present in the retrospective observational studies and must be read
with the appropriate level of caution.
Chemotherapy is the least studied modality of treatment. MCC was initially deemed chemoresistant. (35, 38,
43, 123-125) However more recent studies investigating agents that have been shown to be helpful in small-cell
lung cancer, have shown good results with chemotherapy alone or with RT. (35, 38, 43, 123-125) Among the
chemotherapeutic agents, cyclophosphamide (56%), anthracyclines (49%), and cisplatin (25%) were most
commonly used. (35, 123-125) Although the large meta-analysis of multimodality treatment for MCC by
Medina-Franco et al found no clearly defined role for chemotherapy, other authors have reached differing
conclusions. (30) In a study of chemotherapeutic use over 15 years in 107 cases, Voog et al. reported that the
overall response rate was 60%. (35) The response was 69% in the setting of locally advanced disease and 57%
in metastatic disease. (35) Similar findings were seen in Tai et al’s review of 204 literature based cases. (125)
The TROG looked at the role of chemotherapy in combination with RT in a phase II study (TROG 96:07). (123,
124) Poulsen et al. initially reported high levels of locoregional control and survival benefit of the addition of
chemotherapy to RT in patients deemed “high risk”. (124) “High risk” was defined as having one or more of
the following features: recurrence after initial therapy, involved nodes, primary tumor size greater than 1 cm,
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gross residual disease after surgery, or occult primary with nodes. (124) However, this study was readdressed
by Poulsen et al. in 2006. (123) The subsequent multivariate analysis did not show a significant effect on
survival in a series of 102 “high risk” patients. (123) Patients with pathologically node-negative MCC have a
good prognosis, and adjuvant chemotherapy is not recommended. (35, 123-125) For “high-risk” patients, the
available data for the use of chemoradiotherapy do not support benefit from the addition of chemotherapy to
RT, and adjuvant chemotherapy is not generally recommended in locoregional disease, though may be helpful
in palliation. (35, 123-125) However for the treatment of metastatic disease, chemotherapy is recommended
empirically based on small studies and extrapolation from its use in small-cell lung cancer. (35, 123-125) The
following therapies are most commonly used to treat MCC:

(21)

There are some interesting therapeutic agents being currently researched in animal models. Initial reports of
bcl-2 anti-sense oligonucleotides have inhibited MCC tumor growth in mice when compared with controls and
chemotherapeutics. (126) These data are interesting and may perhaps pave the way for more successful
molecular-target based chemotherapeutics for future treatment of MCC.

Follow-up:
MCCs warrant frequent follow-up because of their aggressive nature. Follow-up should include careful total
body skin examination and palpation of lymph nodes. (1, 21, 22, 94) Additionally, self examination of the skin
may also be useful for patients with MCC to look for both recurrence and other skin malignancies, as they are at
increased risk for other skin cancers. (127) Some studies have implicated serum neuron-specific enolase for
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early detection of recurrence. (1, 21, 22, 94) Routine chest radiograph is indicated, while CT scans of the chest,
abdomen, or head may be required in patients with symptoms suggestive of recurrence. (1, 21, 22, 94) When
recurrence is found, full staging work-up should be performed. See below for NCCN MCC guidelines for
recommended follow-up:

(94)

National Comprehensive Cancer Network Guidelines:
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world’s leading
cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
(128) Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN
develops resources that present valuable information to the numerous stakeholders in the health care delivery
system. (128) NCCN promotes the importance of continuous quality improvement and recognizes the
significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health
care decision-makers. (128) The primary goal of all NCCN initiatives is to improve the quality, effectiveness,
and efficiency of oncology practice so patients can live better lives. (128) The NCCN’s Non-Melanoma Skin
Cancer Panel developed a set of guidelines outlining the treatment of MCC. (94) As MCC is a rare tumor, no
prospective, statistically significant data are available to verify prognostic features or treatment outcomes. (94)
As such, the guidelines are based on lower level of evidence including smaller, institutional studies, metaanalysis, and clinical experience of those individuals on the panel. (94) The following are the official National
Comprehensive Cancer Network (NCCN) guidelines for MCC: (94)
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Clinical Presentation, Preliminary work up and clinical findings

(94)

Primary treatment of clinical N0 (MCC-2)

(94)
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Primary treatment of clinical N1 (MCC-3)

(94)

Treatment of M1 Disease (MCC-4)

(94)
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Follow-up and Recurrences

(94)

Prognosis and Prognostic factors:
The natural history of MCC is variable. (1, 3, 21, 50, 52, 94, 113, 114) In some patients, localized primary
tumors can be indolent and well controlled by local excision alone. (1, 19, 31, 45, 90, 129) Although most
patients present with clinically localized disease, MCC is a particularly aggressive cancer with a propensity for
locoregional recurrence and early lymph node metastases, giving a poor prognosis despite locally confined
disease. (1, 17, 19, 21, 94) The survival rate for patients with MCC and either nodal or systemic disease
parallels that of other particularly aggressive cutaneous malignancies, like melanoma. (1, 17, 19, 21, 94, 127)
Significant favorable prognostic factors for overall survival are initial localized disease, extremity site, female
sex, age less than 65 years, and the absence of comorbid conditions, even after adjusting for the size of the
primary lesion. (19, 22, 97, 113) The presence of nodal disease is the most powerful predictor of survival and
distant metastatic disease. In one series, the median survival for patients with and without involved regional
nodes was 13 versus 40 months, respectively. (122) The following negative prognostic factors are recognized
by the NCCN guidelines for MCC:
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(94)
The site of the primary lesion has been identified as a potential prognostic indicator. Truncal lesions, especially
of the vulva or perianal region, have the worst prognosis. (1, 21, 106, 123-125) However these findings may be
related more to “early” versus “late” detection of lesions than to location specific prognosis. Leg lesions are
associated with a high incidence of local recurrence. (1, 21, 106, 123-125) This could be secondary to one or
more challenges of treatment: the lower extremity commonly has a poor blood supply in older patients, thus
limiting the role of wide surgical resection or the lower leg is poorly tolerant of high-dose irradiation. (1, 21,
106, 123-125)
The following is a summary of the adverse prognostic factors implicated in various literature reviews: (1, 17,
19-22, 30-34, 52, 94, 97, 113, 130)


Nodal disease



Primary > 2cm



Tumor Site



Male Sex



Age greater then 60



Positive surgical margins



Lack of RT in treatment

The only prognostic factor associated with overall survival in the Medina-Franco et al. meta-analysis of
multimodality treatment for MCC was stage at initial diagnosis. (30)
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Following initial therapy, recurrences can be local, regional or distant. The risk of a local recurrence was 43%
in a series of 251 treated at MSKCC. (31) However after a margin-negative excision and re-staging based on
pathological nodal staging, recurrence was only 8%. (31) Local recurrence tends to develops within one year of
initial therapy. (1, 21, 22, 31, 33, 45, 107, 114) Tai et al. reported in their review of 661 literature based cases,
local recurrence in 29%, at a median of four months (range 1 to 96 months). (22) Nodal or distant recurrence
each was a component of the recurrence 33% of cases. (22) Patients with an initial nodal recurrence had a
significantly higher chance of developing subsequent distant metastases than those without a nodal recurrence.
(22)
The impact of a local recurrence on survival is controversial. (1, 21, 22, 31, 33, 34, 45, 114) Tai et al. reported
a median overall survival of 27 months (range 1 to 216 months) among patients who recurred and had salvage
treatments. (22) Combined modality therapy (surgery, RT, chemotherapy) is associated with the best salvage
potential. (1, 21, 22, 31, 125)
The median time to develop clinically detectable nodal recurrence after resection of the primary lesion is seven
to eight months. Among patients with nodal involvement, either at presentation or at recurrence, 11-66% die of
their disease within five years. (1, 21, 22, 31, 33, 34, 45) As with local recurrences, multimodality approaches
are associated with the best outcomes following a nodal recurrence. (1, 21, 22, 31, 125)
Metastatic/systemic disease is associated with an especially bleak prognosis. (1, 21, 22, 94) The mean time to
develop systemic metastases is 18 months; almost 50 % of patients followed for 24 months will develop
systemic recurrence and 65-75% will die of their disease. (1, 21, 22, 42, 43, 94, 107) Once diagnosed with
metastatic MCC, the median survival is estimated at only 9 months. (1, 21, 22, 35, 94) All patients should be
given the option of palliative care. (1, 21, 22, 35, 94)
MCC is a particularly difficult cancer to study. For the clinician, MCC provides and enormous challenge due to
its highly aggressive nature. The best outcomes stem from a multidisciplinary approach to patient care with
input from surgical oncology, radiation oncology, medical oncology, and pathology.
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PURPOSE:
Merkel cell carcinoma (MCC) is a rare of skin cancer and is often described as the most aggressive cutaneous
malignancy. Its high propensity for dermal-lymphatic invasion, local recurrence, and rapid lymphatic and
distant metastasis poses a significant treatment challenge to clinicians. Combining its highly aggressive nature
with its low incidence, merkel cell carcinoma is a particularly difficult cancer to study.
There is no consensus with regard to staging system for MCC. (31, 49, 50) There are two major staging
systems that have been used in the literature: the Memorial Sloan Kettering Cancer Center (MSKCC) MCC
staging criteria and the American Joint Committee on Cancer TNM staging criteria for non-melanoma skin
cancer. Neither staging system, the MSKCC nor the AJCC TNM, has been independently validated for the use
in staging MCC. Such a validation would be helpful in establishing consensus in staging such an aggressive
cancer.
The primary purpose of this study is to validate and compare the Memorial Sloan Kettering Cancer Center
(MSKCC) staging criteria for Merkel cell carcinoma (MCC) with the American Joint Committee on Cancer
(AJCC) TNM staging criteria for non-melanoma skin cancer utilizing the Surveillance, Epidemiology, and End
Results (SEER) database.
Because of the aggressive nature of MCC with high local and regional recurrence following surgery,
postoperative radiation therapy is often used to maximize local and regional control. However, the role of
radiation therapy (RT) remains a highly contested issue, with NCCN treatment guidelines based on limited body
of evidence of retrospective observational studies. (1, 3, 21-23, 31, 34, 41, 44, 49-53, 90, 106, 108, 111-118) In
response to a letter of correspondence, Allen et al. said “A randomized study designed to demonstrate a
reduction in local or regional recurrence from 12% to 6% with the addition of RT would require 281 patients
per arm (one-sided P _ .05, power 0.8), a study that will clearly never be undertaken.” (117)
Agreeing that such a study would be nearly impossible as a randomized prospective endeavor, we sought to
explore the role of RT with a retrospective cohort study design using a similar sized population. Thus, the
secondary purpose of this study is to evaluate the role of RT in the curative (non-metastatic) cohort, using both
MSKCC and AJCC TNM staging criteria, within the SEER dataset.
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METHODS:
HIC approval of this research project and exemption from HIC review were conferred for HIC protocol number
0602001098 under federal regulation 45 CFR 46.101(b)(4). This part of the federal regulations covers research
involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic
specimens, if these sources are publicly available or if the information is recorded by the investigator in such a
manner that subjects cannot be identified, directly or through identifiers linked to subjects. It is also necessary
that the information obtained not be such that if disclosed outside the research, it could reasonably place the
subjects at risk of criminal or civil liability, or be damaging to the subjects’ financial standing, employability, or
reputation. As the HIC chair felt this study met these requirements, exemption and approval were conferred.

Data Source:
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI)
began in 1973 and represents 26% of the US population. Currently SEER coverage includes 23 percent of
African Americans, 40 percent of Hispanics, 42 percent of American Indians and Alaska Natives, 53 percent of
Asians, and 70 percent of Hawaiian/Pacific Islanders. Subjects with cancer registered by SEER are uniquely
identified and followed annually to determine their vital status for as long as he or she lives in a SEER area.(18)
The SEER tumor registries used in this analysis include(18):
From 1973-2002:
•

Connecticut

•

Iowa

•

New Mexico

•

Utah

•

Hawaii

•

Detroit

•

San Francisco-Oakland

From 1974-2002:
•

Atlanta

•

Seattle-Puget Sound

From 1978-2002:
•

10 predominantly black rural counties in Georgia
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From 1980-2002:
•

Native Americans living in Arizona

From 1974-1977 and 2001-2002 (Rejoined in 2001):
•

New Orleans

From 1979-1989 and 2001-2002 (Rejoined in 2001):
•

New Jersey

From 1973-1989:
•

Puerto Rico

From 1992-2002:
•

Los Angeles County

•

4 counties in San Jose-Monterey area

From 2001-2002:
•

Kentucky

•

The rest of California

Additionally, SEER has been collecting information from an independent NCI tumor registry in Alaska. Data
on incident malignancies and follow-up is current through 2002. (18)

Inclusion Criteria:
1.

Date of diagnosis range 1988-2002

2.

Cases of merkel cell carcinoma, ICD-O-3 histology code 8247/3

3.

Microscopically-confirmed pathological diagnosis

4.

Primary anatomic site: Skin

Although the SEER dataset registered cases as far back as the 1970’s, our analysis only evaluated data between
the years of 1988 and 2002 for two major reasons: microscopic-confirmation of diagnosis was not available
within the SEER dataset before 1988 and extent of disease codes were revised in 1988. (18)
One thousand six hundred and ninety seven (1697) cases of malignant merkel cell carcinoma were identified
form the entire 1973-2002 SEER dataset. One thousand five hundred and sixty (1560) cases of malignant
merkel cell carcinoma were identified within the SEER dataset from 1988-2002. Of these, only
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microscopically-confirmed cases were included (n = 1556). Microscopic-confirmation was not available within
the SEER dataset before 1988. Histology was coded according to International Classification of DiseaseOncology-Third Edition (ICD-O-3) codes (8247/3). Cases of benign or in situ MCC were beyond the scope of
this analysis. Specific histological subgroups of MCC were not coded within the SEER dataset. Specific
primary cutaneous site as coded by ICD-O-3 (C44.0 to C44.9) were grouped into anatomic site regions under
convention of prior analyses (17, 19): Upper limb (reference category), Head, Trunk, Lower Limb, and Other.
(17-20, 131, 132)

Exclusion Criteria:
1.

Subjects who did not receive surgery as primary treatment for non-metastatic disease (n = 72)

2.

Subjects who died within four months of diagnosis (n =170 )

3.

Subjects who were not able to be staged by respective staging criteria
a.

MSKCC (n = 995)

b.

AJCC TNM (n = 863)

c.

Both (n = 995)

All subjects who did not receive surgery were excluded from the study, except for those who were found to
have metastasis at initial diagnosis. The reason for this exclusion is that surgery is widely accepted as the
definitive primary treatment for curative intent and according to the National Comprehensive Cancer Network
guidelines the first line treatment for any non-metastatic disease. Subjects, who were found to have metastatic
disease at initial diagnosis, may not have been offered or recommended surgery as a treatment option. For
metastatic disease, the treatment recommendations according to the National Comprehensive Cancer Network,
are to involve Medical Oncology with a multidisciplinary approach to palliative care, +/- systemic
chemotherapy, +/- surgery (as indicated), and +/- radiation therapy (as indicated).
Cases of individual subjects who died within 4 months of diagnosis were excluded from this analysis for the
following two reasons. According to the 1988 SEER Extent of Disease coding manual, the information
pertaining to extent of disease was reported to SEER within a 4 month period following the initial diagnosis.
Therefore if a subject dies within that four month period their SEER information may not be complete. And the
second reason is that those who die within four months of diagnosis may represent a skewed population and not
representative of the disease. They represent those who probably could not have completed a course of
radiation therapy, or may have died from complications after surgery. This population could potentially skew
the analysis of radiation therapy, biasing the data to appear more effective than treatments without radiation.
By removing this population form the analysis, this potential bias is minimized.
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The final population size that met all inclusion and exclusion criteria was 561. The subpopulation of this cohort
of cases who have non-metastatic (no stage IV) disease is the curative cohort (n = 478). The role of RT will be
evaluated in this curative cohort.
The MSKCC staging criteria: (31)
Primary tumor (T)
•
•

T1: Tumor ≤2 cm in greatest dimension
T2: Tumor >2 cm in greatest dimension

Regional lymph nodes (N)
•
•

N0: Negative regional lymph nodes
N1: Positive regional lymph nodes

Distant metastasis (M)
•
•

M0: No evidence of distant metastatic disease
M1: Distant metastatic disease present

MSKCC Stage groups
Stage I
•

T1, N0, M0

Stage II
•

T2, N0, M0

Stage III
•

Any T, N1, M0

Stage IV
•

Any T, any N, M1
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The AJCC TNM staging criteria for non-melanoma skin cancer: (99)
Primary tumor (T)
•
•
•
•
•
•
•

TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: Tumor ≤2 cm in greatest dimension
T2: Tumor >2 cm but ≤5 cm in greatest dimension
T3: Tumor >5 cm in greatest dimension
T4: Tumor invades deep extradermal structures (e.g., cartilage, skeletal muscle, or bone)

Regional lymph nodes (N)
•
•
•

NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastasis
N1: Regional lymph node metastasis

Distant metastasis (M)
•
•
•

MX: Distant metastasis cannot be assessed
M0: No distant metastasis
M1: Distant metastasis

AJCC stage groupings
Stage 0
•

Tis, N0, M0

Stage I
•

T1, N0, M0

Stage II
•
•

T2, N0, M0
T3, N0, M0

Stage III
•
•

T4, N0, M0
Any T, N1, M0

Stage IV
•

Any T, any N, M1
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Constructing the Staging Cohorts:
In order to fit SEER cases into specific MSKCC or AJCC TNM stages, data pertaining to size, lymph node
status, extension, and metastasis had to be extracted from the SEER dataset. This information is encoded within
the 10 digit SEER Extent of Disease code which was revised in 1988. Below are the revised SEER codes from
the SEER Extent of Disease Coding Manual (Third Edition) (18):
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From the 1988-2002 SEER dataset, 561 cases were able to be staged with the MSKCC staging criteria. Six
hundred and ninety six (696) cases fit the AJCC TNM staging criteria. There were 561 cases that could satisfy
both criteria. Of this cohort, there were 478 cases of locoregional disease and 83 cases of metastatic disease.

Covariates:
After careful review of the literature, the following prognostic indicators were identified and included in the
statistical model and analysis: age, primary anatomical site. As the role of radiation treatment within the
curative population remains controversial mainly because of size limited analyses, external beam radiation
therapy is included in this analysis. This study represents the largest population within which the role of
radiation is examined. (17, 19, 20, 33, 131, 132)
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Outcomes:
The primary outcome was overall survival and the secondary outcome was adjusted risk of death, proportional
hazards ratios. SEER participants are followed annually to determine vital status. Date of death is collected at
the local SEER registry and coded, matching cases to state vital statistics. The follow-up time was calculated
from the month and year of the initial date of diagnosis. Overall survival (OS) was calculated with the KaplanMeier method, using the “proc lifetest” program in SAS version 9.1, stratified by stage. Age and RT adjusted
mortality hazard ratios, were calculated with the Cox proportional hazard linear regression method, using the
“proc phreg” program of SAS version 9.1.

Statistical Analysis:
Adjusted Cox proportional hazards linear regression model was constructed for the each staging system cohort.
The model included the covariates: age, stage, primary anatomical site, and +/- external beam radiation therapy.
The following covariates, lacking clear linear relationships with mortality, were entered as categorical (dummy)
variables: stage and primary anatomic site. Interaction variables were constructed to look for interaction
between [radiation treatment and stage] and [radiation treatment and age]. (133)
The adjusted Cox proportional hazards model was optimized to ensure an adequate fit of the final model.
Groups were ordered according to mortality hazards ratios. Groups were consolidated if they did not contribute,
with statistical significance, to clinical mortality differences of the overall model. The likelihood ratio χ2s of the
initial and consolidated models were compared to ensure an adequate fit to the final model. (133)
As this study used preexisting data without identifiers, the Yale University School of Medicine, Human
Investigations Committee (HIC) granted an exemption from review (HIC protocol number: 0602001098). To
protect patient identity and in accordance with SEER guidelines for presentation of public-use dataset, cell
counts ≤ 5 were suppressed in all text and tables. (18, 133)
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RESULTS
Demographics of the Staging Cohort:
The staging cohort comprised of 561 patients with more men than women (ratio 1.6:1) and whites as the largest
representative race (ratio to next largest race 20.1:1). The median follow-up time was 2.2 years with a range of
0.4-14.3. The median age was 75 years with a range of 22-98. The most common cutaneous primary site was
head and neck (39%), followed by upper extremity (24%). There was an increasing incidence of MCC as
represented by increased diagnoses from 1988 to 2002 in five year blocks, which is consistent with recent
findings by Hodgson. (20) The demographic of the staging cohort (see table 1) is consistent with prior
epidemiological studies. (17, 19, 20)
Baseline Demographics (Table 1)
n = 561 patients

Size of Staging Cohort
•

Median Age

75 years

•

Mean Age

73 years

•

Standard Deviation

12 years

•

Age Range

22-98 years

Number of

Percentage

Patients
Sex
•

Male

342

61%

•

Female

219

39%

Year of Diagnosis:
•

1988-1992

126

23%

•

1993-1997

191

34%

•

1998-2002

299

53%

•

White

502

89%

•

Asian/Pacific Islander

25

4%

•

Hispanic

23

4%

•

Black

6

1%

•

Other

11

2%

Race:*
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Primary Anatomic Site:
•

Head and Neck

218

39%

•

Upper Extremity

133

24%

•

Lower Extremity

94

17%

•

Trunk

82

15%

•

Other

34

5%

* in accordance with SEER guidelines to protect patient confidentiality, cell sized smaller than 5 are not
reported.
The population comprised largely of the elderly, with over 75% of the cohort over the age of 60 years old. This
is consistent with prior epidemiological studies as MCC has been found to have a predilection for the elderly.
(17, 19, 20) (See figure 1)

Population by 5-Year Age Groups (Figure 1)
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This population distribution graphically demonstrated the skew of the staging cohort to the elderly consistent
with prior epidemiological studies. (Figure 1)

58
The following two tables summarize the characteristics of the various criteria that were used to stage the SEER
population to the two staging systems.

Size Summary Statistics (Table 2)
n=

Percentage

561

Size

Mean

Standard

Range (cm)

(cm)

Deviation

2.63

3.71

0 - 57

•

≤ 2cm

272

49%

1.22

0.55

0-2

•

> 2cm

175

31%

4.79

5.19

2.1 – 57

•

Not sized

114

20%

By MSKCC Stage
•

Stage I

224

40%

1.22

0.54

0.2 - 2

•

Stage II

114

20%

4.15

3.36

2.1 - 30

•

Stage III*

140

25%

2.75

2.42

0 - 14

•

Stage IV*

83

15%

6.03

9.36

0 - 57

By AJCC TMN Stage
•

Stage I

223

40%

1.22

0.54

0.2 - 2

•

Stage II

107

19%

4.17

3.43

2.1 - 30

•

Stage III*

148

26%

2.83

2.39

0 - 14

•

Stage IV*

83

15%

6.03

9.36

0 - 57

Local/regional Disease

478

•

No RT

246

51%

2.39

2.76

0 - 30

•

RT

232

49%

2.21

2.00

0 - 17

Lymph Node Status*
•

Negative*

355

63%

•

Positive*

163

29%

•

Metastatic*

16

3%

•

Unknown*

26

5%

* many not sized
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Of the entire staging cohort the median survival was 4.42 years with a range of 0.42-14.33 and 50% received
post-operative RT. As all patients who either died or were lost to follow up within four months of date of
diagnosis, the first death available for use in the analysis was at five months (or 0.42 years). After staging the
cohort by MSKCC criteria, there were 224 patients in Stage I (40%), 114 patients in Stage II (20%), 140
patients in Stage III (25%), and 83 patients in Stage IV (15%). After staging the cohort by AJCC TNM criteria,
there were 223 patients in Stage I (40%), 107 patients in Stage II (19%), 148 patients in Stage III (26%), and 83
patients in Stage IV (15%). The locoregional disease cohort (patients without metastasis at initial diagnosis)
represents those patients with whom treatment was intended to be curative. Of the locoregional disease cohort
staging cohort the median survival was 4.74 years with a range of 0.42-14.33 and 51% received post-operative
RT. See table 4 for summary survival statistics by MSKCC and AJCC TNM stage.

Survival Summary Statistics (Table 3)
n=

Median survival

Percentage

561

Median

Mean

Standard

Survival

Survival

Error

(yrs)

(yrs)

4.42

5.36

0.22

0.42-14.33

Range (yrs)

By MSKCC Stage
•

Stage I

224

40%

6.08

6.48

0.35

0.42-14.33

•

Stage II

114

20%

4.33

4.38

0.30

0.42-11.58

•

Stage III

140

25%

2.91

4.67

0.42

0.42-11.33

•

Stage IV

83

15%

1.50

2.73

0.28

0.42-12.25

By AJCC TMN Stage
•

Stage I

223

40%

6.17

6.51

0.35

0.42-14.33

•

Stage II

107

19%

4.50

4.45

0.32

0.42-11.58

•

Stage III

148

26%

2.92

4.53

0.39

0.42-11.33

•

Stage IV

83

15%

1.50

2.73

0.28

0.42-12.25

4.42

5.36

0.22

0.42-14.33

Whole Cohort

561

•

No RT

280

50%

3.58

5.09

0.30

0.42-13.00

•

RT

281

50%

4.50

5.63

0.31

0.42-14.33

4.75

5.64

0.23

0.42-14.33

Local/regional Disease

478

•

No RT

246

51%

4.75

5.34

0.32

0.42-13.00

•

RT

232

49%

4.67

5.93

0.34

0.42-14.33
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MSKCC Staging Criteria as a Valid Staging System for MCC:
In the survival analysis of MCC by MSKCC stage, all stages demonstrated appropriate relationships to each
other with stage having a better overall survival than the subsequent stage: Stage I > Stage II > Stage III >
Stage IV. In the Kaplan-Meier survival plot below, Stage I is depicted in black; Stage II in red; Stage III in
green; and Stage IV in blue.

The five-year overall survival was 59.3% for stage I, 44.6% for stage II, 32.5% for stage III, and 28.3% for
stage IV. This data is consistent with overall survival statistics reported in the literature.
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A Cox proportional hazards regression model was constructed for the MSKCC staged population using the
following variables: age, RT status, MSKCC stage, and site of primary. When compared with stage I, the age
and RT adjusted mortality hazard ratio (HR) was 1.44 (95% CI 1.03-2.00) for stage II, 2.14 (95% CI 1.57-2.93)
for stage III, and 2.61 (95% CI 1.85-3.67) for stage IV. (See table 4)

Age and RT Adjusted Cox Proportional Hazards Mortality Hazard Ratio by MSKCC stage (Table 4)

MSKCC Stages (n=561)
Stage

HR

95% CI

P=

Stage I

1.00

Reference

-

Stage II

1.44

1.03-2.00

0.0335

Stage III

2.14

1.57-2.93

<0.0001

Stage IV

2.61

1.85-3.67

<0.0001

Bold Items were statistically different than reference values.
That each stage’s mortality HR is both greater than 1.00 and increasing with each subsequent stage, supports the
prior claim that the MSKCC criteria appropriately risk stratifies this SEER cohort. Furthermore that the 95%
confidence intervals do not cross 1.00 lends statistical significance with P < 0.05 for all stages in comparison
with stage I. Thus, the cohort staged by the MSKCC staging criteria both appropriately and significantly risk
stratified this SEER cohort.

62
AJCC TNM Staging Criteria as a Valid Staging System for MCC:
In the survival analysis of MCC by AJCC TNM stage, all stages demonstrated appropriate relationships to each
other with stage having a better overall survival than the subsequent stage: Stage I > Stage II > Stage III >
Stage IV. In the Kaplan-Meier survival plot below, Stage I is depicted in black; Stage II in red; Stage III in
green; and Stage IV in blue.

The five-year overall survival was 59.7% for stage I, 47.1% for stage II, 31.0% for stage III, and 28.3% for
stage IV. This data is consistent with overall survival statistics reported in the literature as well as comparable
to the five-year overall survival data from the MSKCC staged cohort.

63
A Cox proportional hazards regression model was constructed for the AJCC TNM staged population using the
following variables: age, RT status, AJCC TNM stage, and site of primary. When compared with stage I, the
age and RT adjusted mortality HR was 1.41 (95% CI 0.99-1.99) for stage II, 2.13 (95% CI 1.57-2. 89) for stage
III, and 2.62 (95% CI 1.86-3.69) for stage IV. (See table 5)

Age and RT Adjusted Cox Proportional hazards ratio of AJCC TNM Stages (Table 5)
AJCC TNM Stages (n=561)
Stage

HR

95% CI

P=

Stage I

1.00

Reference

-

Stage II

1.41*

0.99-1.99*

0.0525

Stage III

2.13

1.57-2.89

<0.0001

Stage IV

2.62

1.86-3.69

<0.0001

* AJCC TNM Stage II was not statistically different from AJCC TNM Stage I (p = 0.0525)
Bold Items were statistically different than reference values.
That each stage’s mortality HR is both greater than 1.00 and increasing with each subsequent stage, supports the
prior claim that the AJCC TNM criteria appropriately risk stratifies this SEER cohort. However that the 95%
confidence intervals cross 1.00 for stage II, implies that there is no statistical difference between AJCC TNM
stages I and II with respect to survival. Although there is not statistical significant difference between stages I
and II, this lack of statistical significance is small enough that a larger population analysis might show a
statistically significant difference between stage I and II. That the 95% confidence intervals do not cross 1.00
for stages III and IV means that they are statistically different in comparison with stage I, with P < 0.05.
Therefore, although the cohort staged by the AJCC TNM staging criteria appropriately risk stratified this SEER
cohort, it was not successful in significantly risk stratified this SEER cohort.
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Comparison of Staging Systems:

MSKCC Stages (n=561)

AJCC TNM Stages (n=561)

Stage

n

Five-year overall survival

n

Five-year overall survival

Stage I

n=224

59.3%

n=223

59.7%

Stage II

n=114

44.6%

n=107

47.1%

Stage III

n=140

32.5%

n=148

31.0%

Stage IV

n=83

28.3%

n=83

28.3%

MSKCC Stages (n=561)

AJCC TNM Stages (n=561)

Stage

HR

95% CI

P=

HR

95% CI

P=

Stage I

1.00

Reference

-

1.00

Reference

-

Stage II

1.44

1.03-2.00

0.0335

1.41*

0.99-1.99*

0.0525

Stage III

2.14

1.57-2.93

<0.0001

2.13

1.57-2.89

<0.0001

Stage IV

2.61

1.85-3.67

<0.0001

2.62

1.86-3.69

<0.0001

* AJCC TNM Stage II was not statistically different from AJCC TNM Stage I (p = 0.0525), though it was
trending toward statistic significance (P < 0.065).
Bold Items were statistically different than reference values.
Close comparison of these two staging systems demonstrates a subtle but statistically significant difference in
the way these staging criteria risk stratify the SEER cohort. Both staging systems appropriately risk stratify this
SEER cohort. However, the data demonstrate a clear statistical difference for only the MSKCC staged
population. As such, the MSKCC staged population is the only staging system to significantly risk stratify the
SEER cohort.
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The Role of Radiation Therapy in Population with Curative Intent:
The role of RT was analyzed by looking at the mortality hazard ratios of postoperative radiation therapy status
in the Cox Proportional Hazard model of the SEER cohort adjusted for age and stage. The following is the
summary statistical data of the curative cohort by RT status. (See table 6)

RT Status Summary Statistics (Table 6)
n=

Percentage

RT Status
No RT

RT

n (%)

n (%)

Size
•

≤ 2cm

272

49%

143 (53%)

129 (47%)

•

> 2cm

175

31%

89 (51%)

86 (49%)

•

Not sized

114

20%

48 (42%)

66 (58%)

Lymph Node Status
•

Negative

355

63%

200 (56%)

155 (44%)

•

Positive

163

29%

61 (37%)

102 (63%)

•

Metastatic

16

3%

9 (56%)

7 (44%)

•

Unknown

26

5%

10 (38%)

16 (62%)

By MSKCC Stage
•

Stage I

224

40%

126 (56%)

98 (44%)

•

Stage II

114

20%

67 (59%)

47 (41%)

•

Stage III

140

25%

53 (38%)

87 (62%)

•

Stage IV

83

15%

34 (41%)

49 (59%)

By AJCC TMN Stage
•

Stage I

223

40%

125 (56%)

98 (44%)

•

Stage II

107

19%

64 (60%)

43 (40%)

•

Stage III

148

26%

57 (39%)

91 (61%)

•

Stage IV

83

15%

34 (41%)

49 (59%)
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Among 478 patients with local or regional disease, 49% received radiation. The following table represents the
summary survival statistics of the curative cohort by RT status. (See table 7)

Summary Survival Statistics of Curative Cohort by RT Status (Table 7)
n=

Local/regional Disease

Percentage

478

Median

Mean

Standar

Range (yrs)

Survival

Survival

d Error

(yrs)

(yrs)

4.75

5.64

0.23

0.42-14.33

•

No RT

246

51%

4.75

5.34

0.32

0.42-13.00

•

RT

232

49%

4.67

5.93

0.34

0.42-14.33

The previous graph is a plot of the Kaplan-Meier survival curves stratified by RT status. Patients who did not
receive RT are represented in black; and those who received RT are represented in red. Notice that the patients
who received RT tended to live longer, though this difference was not a statistically significant.
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After adjusting for MSKCC stage and age, radiation did not have a statistically significant mortality HR, HR
0.83 (95% CI 0.63-1.09). Similarly, in the AJCC TNM staged population radiation did not have a statistically
significant mortality HR, HR 0.83 (95% CI 0.63-1.09). (See table 8)

Roll of RT by Age Adjusted Stage (Table 8)
MSKCC Stages (n=478)

AJCC TNM Stages (n=478)

Stage

RT HR

95% CI

P=

RT HR

95% CI

P=

Stage I

1.01

0.65-1.56

0.9727

1.02

0.66-1.58

0.9343

Stage II

0.82

0.46-1.45

0.4606

0.76

0.41-1.41

0.3846

Stage III

0.73

0.46-1.15

0.1747

0.75

0.49-1.16

0.1952

None were found to be significant within each stage
A Hazard Ratio (HR) below 1.00 signifies improved survival. With HR trending downward with stage, the role
of RT seems to be more beneficial to survival for the advanced staged malignancies than the early staged,
though not significantly. As the HR and P values are both decreasing as stage is increasing, a trend towards
significance of is noted as well as an increasing benefit from the RT as the HR decreases.

Interaction variables:
MSKCC
In the model without an interaction term, radiation is not significantly correlated with survival. The interaction
between radiation and stage is not significant (P=0.69), indicating that the lack of correlation between radiation
and stage is consistent across all stages.
AJCC TNM
In the model without an interaction term, radiation is not significantly correlated with survival. The interaction
between radiation and stage is not significant (P=0.42), indicating that the lack of correlation between radiation
and stage is consistent across all stages.
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DISCUSSION:
Although MCC was initially described as an indolent tumor with low malignant potential, current evidence
implicates MCC as one of the most aggressive cutaneous malignancies. Although there have been an increasing
number of studies that have further characterized MCC, there remains much about this cancer that is unknown.
By far the greatest challenge to research has been the rarity of this particular malignancy. It is the decreased
incidence that limits the body of evidence to retrospective, observational, single institution studies and metaanalytical reviews of multiple studies. This study represents the largest single source cohort analysis of MCC to
date. The only two other studies that have over 500 cases are literature review based. The demographic data
from this study is consistent with that of prior studies.
There is no consensus with regard to staging system for MCC. Neither staging system, the MSKCC nor the
AJCC TNM, has been independently validated for the use in staging MCC. The results of this study
demonstrate that the MSKCC staging criteria both appropriately and significantly risk stratifies the SEER
cohort for all stages. This data validates the continued use of this staging system for appropriate risk
stratification of patients with MCC.
The data did not show significant risk stratification for the AJCC TNM staging criteria. However a subsequent
study with a larger population may demonstrate a statistically significant difference between AJCC TNM stages
I and II, as the P = 0.0525 approached statistical significance. Although the risk stratification is appropriate and
approaches statistical significance, this data when compared to the data from the MSKCC staged cohort,
suggest that the MSKCC staging criteria do a better job of risk stratifying.
MCC remains an enormous challenge for the clinician because these tumors have a propensity for local
recurrence, nodal involvement and distant spread. The best outcomes stem from a multidisciplinary approach to
patient care with input from surgical oncology, radiation oncology, medical oncology, and pathology.
According to the results of this study, radiation therapy was not shown to confer a survival advantage to the
curative cohort regardless of stage or staging system.
The SEER database contains a wealth of information and can be a powerful resource for studying many cancers,
especially ones of profound rarity like merkel cell carcinoma. However, there are several significant limitations
of the SEER dataset, which are particularly challenging for outcomes analyses based on treatment. Overall
survival statistics are the most reliably reported outcome that can be analyzed through SEER. Cause specific
survival, although very important in outcomes analysis, is not reliably reported for SEER, especially for a rare
cancer like MCC. Such an analysis would depend on correct reporting of actual cause of death. For a poorly
understood aggressive cancer like merkel cell carcinoma, the data is far less reliable. Additionally, three
important factors are not reported within the SEER database: chemotherapy, margin status, and disease
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progression (i.e. local, regional, or distant metastatic recurrence). Although the role of chemotherapy is unclear
for MCC, some preliminary studies have reported benefit. (123-125) Margin status for any cancer whose
definitive primary treatment is surgery with wide surgical margins, would play an important role in any
outcomes analysis. In particular the role of radiation therapy is believed to decrease the risk of local and
regional recurrence.
Radiation may play a significant role in local/regional control, though this study would not be able to address
that question. As SEER does not report margin status, chemotherapy, or local/regional recurrence, the role of
radiation therapy could not be completely assessed. Given the limitations of the SEER database the role of
radiation for local/regional control and cause specific survival would have to be more thoroughly examined by
another study. Only a large meta-analysis like those done by Tai et al and Medina-Franco et al or a single
institution like MSKCC with enough cases of MCC could address a more thorough evaluation of the complete
role of radiation therapy.
Additionally this study and future studies could be improved by examining the role of depth of extension as a
prognostic factor. Considering that MCC shares the highly aggressive qualities as melanoma, depth may have a
significant prognostic value. Given MCC’s predilection for the elderly, perhaps including medicare data on the
patients that qualify, may improve scope of this project.
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CONCLUSION:
MCC is a particularly rare form of skin cancer. Derived from neuroendocrine origin, MCC has been described
as the most aggressive form of cutaneous malignancy. MCC appears to have a predilection for the elderly and a
propensity for dermal-lymphatic invasion along with rapid nodal and hematogenous spread. The tumor has
been shown to share many similarities with small-cell carcinoma of the lung, including treatment options and
metastatic potential. Although treatment regimes often include combined modality therapy, early detection and
complete surgical resection remain the foundation of the best treatment outcomes.
Unfortunately, MCC is a relatively poorly understood cancer. Current management tends to be based on
institutional experience and convention, with limited literature to support specific treatments. The majority of
literature are single institution, retrospective, observational studies with populations significantly low enough to
challenge most conclusions. By far the greatest challenge to research contributing to the relatively limited fund
of knowledge that exists in the current literature has been the rarity of this particular malignancy. The very low
incidence of MCC limits the body of evidence to retrospective, observational, single institution studies and
meta-analytical reviews of multiple studies. This study represents the largest single source cohort analysis of
MCC to date. The only two other studies that have over 500 cases are literature review based.
In addition to the limited number of treatment studies, there remains no consensus with respect to staging. The
two staging systems most commonly used in the literature are the MSKCC staging system for MCC and the
AJCC TNM staging system for non-melanoma skin cancer. Thus far there has not been a clear independent
validation study that compares these staging systems to the knowledge of these authors. All these factors
combine, creating a multitude of challenges for the clinician managing the patient with MCC. The results of
this study demonstrate that the MSKCC staging criteria both appropriately and significantly risk stratifies the
SEER cohort for all stages. These data validate the continued use of this staging system for appropriate risk
stratification of patients with MCC. The data did not show significant risk stratification for the AJCC TNM
staging criteria. Although the risk stratification is appropriate and approaches statistical significance, these
data, when compared with the data from the MSKCC staged cohort, suggest that the MSKCC staging criteria do
a better job of risk stratifying this SEER cohort.
Radiation therapy was not shown to confer a survival advantage to the curative cohort regardless of stage or
staging system. As SEER does not report margin status, chemotherapy, or local/regional recurrence, the role of
radiation therapy could not be completely assessed. For a cancer as rare as MCC, the data for cause of death is
not reliable; therefore cause specific survival can not be reliably calculated. Radiation may play a significant
role in local/regional control, though this study would not be able to address that question. Given the
limitations of the SEER database the role of radiation for local/regional control and cause specific survival
would have to be more thoroughly examined by another study.
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